Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Marisi, Giorgia, Cucchetti, Alessandro, Ulivi, Paola, Canale, Matteo, Cabibbo, Giuseppe, Solaini, Leonardo, Foschi, Francesco G, De Matteis, Serena, Ercolani, Giorgio, Valgiusti, Martina, Frassineti, Giovanni L, Scartozzi, Mario, Casadei Gardini, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158485/
https://www.ncbi.nlm.nih.gov/pubmed/30271080
http://dx.doi.org/10.3748/wjg.v24.i36.4152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158485/
https://www.ncbi.nlm.nih.gov/pubmed/30271080
http://dx.doi.org/10.3748/wjg.v24.i36.4152

Ejemplares similares